NVLX Nuvilex, Inc. Reaches Unofficial Starting Line of Its Phase 3 Pancreatic Cancer Clinical Trials
Nuvilex, Inc. Reaches Unofficial Starting Line of Its Phase 3 Pancreatic Cancer Clinical Trials
NEW YORK, NY--(Marketwired - Nov 5, 2013) - Nuvilex, Inc. (OTCQB: NVLX) made an announcement yesterday that should have investors excited that the company's Phase 3 clinical trials may have unofficially just started. Nuvilex announced that cloning of the cancer-drug-activating cells required for its future Phase 3 clinical trials has begun at Inno Biologics in its cGMP-compliant facilities. Given that the work Inno Biologics is doing can be considered the most important in the process outside of actually enrolling patients in the Phase 3 trials, yesterday's news could be the trial's unofficial starting line.
The company reported yesterday that following receipt by Inno Biologics of four vials of frozen cells capable of converting the well-known anticancer prodrug ifosfamide into its active cancer-killing form, one of the vials was thawed and the cells grown in culture. These are the cells that were previously grown by ViruSure in Vienna, Austria. According to Inno Biologics, the cells were successfully thawed, and approximately 97% of the cells were found to be viable.
Nuvilex explains the cloning process consists of growing cells in multiple microplates to produce a large number of discrete clones. "State-of-the-art" technology is then used in the cloning isolation process. After additional rigorous biochemical testing, those clones determined to be the "best" for Nuvilex's oncological purposes will be selected and additional testing will be done. The company says in the end, the best clones will be propagated to obtain large numbers of cells required for Nuvilex's late-phase clinical trials.
These are truly exciting times for the investors at Nuvilex, Inc. as the company continues on its march towards head to head Phase 3 clinical trials with Eli Lilly and Celgene. To get a better understanding of how the clinical trials will unfold, the trial's sites, SG Austria's role in the trials and much more, listen to our interview with Nuvilex's COO, Dr. Gerry Crabtree: www.stockmarketmediagroup.com/media
About Stock Market Media Group
Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Research Reports, CEO Interviews and Feature Articles. For more information and to read disclaimers and disclosures: www.stockmarketmediagroup.com
Contact:
Stock Market Media Group
Email Contact
Nuvilex, Inc. Reaches Unofficial Starting Line of Its Phase 3 Pancreatic Cancer Clinical Trials
NEW YORK, NY--(Marketwired - Nov 5, 2013) - Nuvilex, Inc. (OTCQB: NVLX) made an announcement yesterday that should have investors excited that the company's Phase 3 clinical trials may have unofficially just started. Nuvilex announced that cloning of the cancer-drug-activating cells required for its future Phase 3 clinical trials has begun at Inno Biologics in its cGMP-compliant facilities. Given that the work Inno Biologics is doing can be considered the most important in the process outside of actually enrolling patients in the Phase 3 trials, yesterday's news could be the trial's unofficial starting line.
The company reported yesterday that following receipt by Inno Biologics of four vials of frozen cells capable of converting the well-known anticancer prodrug ifosfamide into its active cancer-killing form, one of the vials was thawed and the cells grown in culture. These are the cells that were previously grown by ViruSure in Vienna, Austria. According to Inno Biologics, the cells were successfully thawed, and approximately 97% of the cells were found to be viable.
Nuvilex explains the cloning process consists of growing cells in multiple microplates to produce a large number of discrete clones. "State-of-the-art" technology is then used in the cloning isolation process. After additional rigorous biochemical testing, those clones determined to be the "best" for Nuvilex's oncological purposes will be selected and additional testing will be done. The company says in the end, the best clones will be propagated to obtain large numbers of cells required for Nuvilex's late-phase clinical trials.
These are truly exciting times for the investors at Nuvilex, Inc. as the company continues on its march towards head to head Phase 3 clinical trials with Eli Lilly and Celgene. To get a better understanding of how the clinical trials will unfold, the trial's sites, SG Austria's role in the trials and much more, listen to our interview with Nuvilex's COO, Dr. Gerry Crabtree: www.stockmarketmediagroup.com/media
About Stock Market Media Group
Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Research Reports, CEO Interviews and Feature Articles. For more information and to read disclaimers and disclosures: www.stockmarketmediagroup.com
Contact:
Stock Market Media Group
Email Contact
